New drugs that spur weight loss and deal with diabetic issues are already using the public—and also the pharmaceutical field—by storm. The newest entrant, Zepbound, recently joined copyright, Wegovy, Victoza and others in a rising course of drugs identified as GLP-one receptor agonists.. It claims it’s “GLP-one encouraged,” but there’s